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Introduction
Congenital adrenal hyperplasia (CAH) is a spectrum of 
inherited autosomal recessive mutations affecting the 
enzymatic steps required for adrenal steroid synthesis 
[1]. The global prevalence of classic CAH is 1:15,000 
people [2]. However, a higher prevalence (1:1209) was 
reported among Egyptian newborns based on the bio-
chemical analysis of 17-hydroxy progesterone levels 
(17OHP) [3]. Clinically, CAH is classified into different 
phenotypes: classic [including salt-wasting (SW) and 
simple virilizing (SV) forms] and non-classic (NC). In 
SW CAH, crises in the form of hypovolaemia, hypona-
traemia, and hyperkalaemia start early in the neonatal 
period associated with ambiguous genitalia in females 
and elevated adrenal precursors (17OHP, delta-4 andro-
stenedione, and testosterone). SV CAH presents with 
precocious puberty in boys and a variable degree of 
virilization in girls in the presence of elevated 17OHP 
with no clinical or biochemical evidence of SW crisis [4]. 
The cornerstone treatment is glucocorticoid re-
placement, preferably at a hydrocortisone level of 
10–15 mg/m2/day [5]. Lifetime monitoring and regular 
dose adjustment of glucocorticoids and mineralocorti-
coids are crucial in the management of CAH patients, to 
optimize growth and pubertal development [6]. Insuf-
ficient steroid therapy results in inadequate suppression 
of excessive androgen secretion, which leads to abnor-
mal accelerated skeletal maturation with subsequent 
early epiphyseal fusion and suboptimal final adult 
height (FAH). Conversely, excessive steroid dose can 
directly suppress growth via a direct effect on growing 
growth plates. The main challenge in the management 
of patients with CAH is to minimize the fluctuations 
between hyperandrogenaemia and hypercortisolism, 
which occur due to the short half-life (one hour) of 
hydrocortisone [1,7]. Previous observational studies and 
meta-analyses have reported reduced FAH in CAH pa-
tients compared to normal populations, as well as their 
parental genetic potentials [6]. Height prediction based 
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BA was assessed at the onset of puberty from an X-ray of the left 
hand and wrist using the Greulich and Pyle method [13], and 
predicted adult height (PAH) was calculated by Bayley-Pinneau 
(B&P) [14] prediction using the appropriate tables for girls and 
boys according to the relation of bone age to chronological age 
(CA) whether average (BA within one year of CA), retarded, or 
accelerated [13]. Gain in height was defined as FAH-PAH at the 
onset of puberty. Written informed consent was obtained from 
all participants. The study was approved by the Research Ethics 
Committee of Cairo University (IRB: I-091017) and conducted in 
accordance with the Helsinki Declaration. 
Statistical methods
Descriptive analyses were presented as mean ± standard devia-
tion (SD) or median and interquartile range (IQR) for numerical 
variables or number and percentages for categorical variables. 
Comparison between numerical variables was performed using 
the Mann-Whitney U test. Comparison between categorical data 
was performed using the chi-square test or Fisher ’s exact test. 
Correlations were performed using Spearman correlation coef-
ficient test. P value ≤ 0.05 was considered significant, and highly 
significant if < 0.01. SPSS software (version 16 windows) was used 
for data analysis. 
Results
Demographic data
Fifty-four patients with classic CAH were included. 
The female:male ratio was 40:14 (74.1% vs. 25.9%). 
The median age in the study group was 20 years (IQR 
20–28). Twenty-three patients (42.6%) were diagnosed 
as SW CAH (18 females, 5 males), and 31 patients 
(57.4%) were SV CAH (22 females, 9 males). Median 
age at diagnosis of patients with SW CAH was as early 
as 8 weeks (IQR: 4.5–16, range: 0.14–17.1 weeks), and it 
was 2.75 years (IQR: 0.75–4.5, range: 0.09–11.65 years) 
for SV CAH patients. All patients were treated entirely 
with hydrocortisone as glucocorticoid replacement 
therapy in three divided daily doses. The median dose 
of hydrocortisone among the whole studied group was 
15 mg/m2/day (IQR: 10.7–20). Fludrocortisone was used 
by 46 patients (85.2%). Nine patients (16.7%) received 
LHRH analogue to delay pubertal onset. Puberty was 
early in 38.7 % of patients, normal in 21.3%, and de-
layed in 40%. Menarche was early in12.5%, occurred 
at a normal age in 3%, and was delayed in 84.3%. Two 
females had polycystic ovarian syndrome (PCOS), 
and three males had TART. The clinical characteristics 
and hormonal profile at the age of pubertal onset are 
shown in Table 1. 
Auxological data
Auxological and BA data of the study group are pre-
sented in Table 2. Chronological age (CA) was delayed 
compared to BA at onset of puberty. Twenty-nine 
cases (53.7%) had BA within one year of CA, 7 patients 
(13%) had delayed BA, and 18 patients (33.3%) had 
advanced BA.
on bone age using the Bayley-Pinneau (B&P) method 
seeks to determine the potential for growth and may 
help with crucial clinical decisions [8]. 
Our goal in this study was to test the validity of the 
B&P method in predicting FAH at the onset of puberty 
in children with classic CAH (SW or SV). We also aimed 
to identify factors that influence FAH.
Material and methods
This was a retrospective longitudinal observational single-centre 
study conducted in the Diabetes Endocrine and Metabolism Pae-
diatric Unit (DEMPU), The Children’s Hospital, Cairo University 
on a convenience sample of patients. 
Inclusion criteria
All patients, male or female, with classic CAH due to 21-hydroxylase 
deficiency, whether SW or SV, who had been regularly followed up 
in our clinic since diagnosis, had achieved FAH, and had undergone 
an X-ray of the left hand and wrist at the onset of puberty for bone 
age (BA), were eligible for evaluation. The onset of puberty was 
defined by a testicular size of 4 mL (T2) in male children and a breast 
size of B2 in females [9]. FAH was defined as a growth velocity < 
1 cm in the previous year and/or a bone age > 15 years in females 
or > 16 years in males or height recorded after the age of 20 years 
in males or 18 years in females [10]. 
Exclusion criteria
Patients with skeletal or other chronic growth-altering disorders or 
those who received growth hormone were excluded. 
Data at diagnosis and height at the onset of puberty were retrieved 
from patients’ files. Because genetic diagnosis was not available, the 
diagnosis of classic CAH was based on clinical and biochemical data 
(done after organic extraction) and patients were divided into SW 
or SV for comparison: a) salt-wasting form (SW) – salt-wasting crisis 
started early in the neonatal period in the form of hypovolaemia, 
hyponatraemia, or hyperkalaemia, associated with ambiguous 
genitalia in females with confirmatory elevated adrenal precur-
sors (17-hydroxy progesterone-androstenedione-testosterone); 
b) simple virilising form (SV) — precocious puberty in boys and 
variable degree of virilization in girls in the presence of elevated 
17-hydroxy progesterone (17OHP) with no clinical or biochemical 
evidence suggestive of SW crisis.
History included the following: age at diagnosis, age at time of 
study, onset of puberty and menarche in females, and detailed 
therapy at the time of puberty — hydrocortisone dose, fludrocorti-
sone dose, and luteinising hormone-releasing hormone analogues 
(LHRHa) to delay puberty. Results of hormonal analyses from 
samples taken at 8 a.m. at the time of BA were retrieved from patient 
files (17OHP, testosterone, delta-4-androstenedione). Adequate 
steroid replacement at time of puberty was defined by a 17OHP 
level of 5-7 ng/mL [7] with lower levels considered as over-treatment 
[except in males with testicular adrenal rest tumours (TART) where 
lower levels are desirable to suppress ACTH levels [11], and higher 
levels as under-treatment].
Anthropometric measurements were performed according to In-
ternational Biological Programme [12]. Body weight was measured 
using the Seca scale. The weight was recorded to the nearest 0.1 kg. 
FAH was measured using a Harpenden stadiometer and recorded 
to the nearest 0.1 cm. Body mass index (BMI) was calculated as 
weight (kg)/height (m)2. Target height (TH) was calculated from 
the data of parental measurements, as follows: maternal height + 
paternal height + or – 13 cm for males and females, respectively/2. 
Standard deviation scores for body weight, height, BMI, and tar-
get height (TH) were calculated using a Growth Vision computer 
system software provided by Novonordisc.
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Target height was available for 27 patients. The 
median target height SDS (–0.8) was significantly 
higher than the median FAH SDS (–2.2) (p < 0.001). 
The median PAH SDS at the onset of puberty (–1.5) 
was also significantly greater than the median FAH SDS 
(–2.2) (p < 0.001). FAH and FAH SDS were significantly 
worse in females (150.36 ± 7.23; –2.05 ± 1.13) than in 
their male counterparts (162.86 ± 3.30; –1.53 ± 0.51) 
(p value < 0.001; 0.048) (Tab. 3).
Evaluation of FAH according to CAH type among 
the whole cohort revealed that there were no dif-
ferences between SW and SV regarding CA/BA at 
time of puberty, FAH, or FAH/TH, (Tab. 4). However, 
males with SW CAH had significantly lower FAH SDS 
(–2.5 ± 0.44) than males with SV CAH (–1.33 ± 0.38) 
(p value 0.01). There was no difference between females 
with SW CAH and those with SV CAH regarding FAH 
SDS (p value 0.67) (Tab. 3). Additionally, male patients 
on lower hydrocortisone dose (HC < 15 mg/m2/d) 
had significantly better FAH SDS (–1.31 ± 0.25) when 
compared to males on higher dose (–1.84 ± 0.59), with 
p value = 0.04. 
Concerning metabolic control guided by the 
level of 17OHP levels at puberty, 17 (31.5%) patients 
had suppressed levels, 8 patients (14.8%) had levels 
within the desired range, and 29 patients (53.7%) 
had levels above the desired range. There was no 
difference in FAH between those with good control 
at the time of onset of puberty and those with poor 
control (median = –1.5, IQR: –2.7, –1.35 vs. –2.1, 
IQR: –2.6, –1.25) (p = 0.06). In patients with good 
control, there was no difference between PAH and 
FAH SDS. Also, TH was available for 6/8 patients 
with good control. TH was significantly higher than 
PAH in these patients (–1.1 ± 0.68 SD vs. –2.0 ± 0.78 
SD, p = 0.03). In patients with poor control (over- or 
under-treated) FAH was significantly lower than 
PAH. TH was available for 21/46 patients with poor 
control, and TH was significantly higher than PAH 
in these patients (–0.8 ± 1.07 SD vs. –1.41 ± 1.09 SD, 
p = 0.03) (Tab. 5).
There was a negative correlation between final 
height SDS on the one hand and BA at onset of puberty 
(r = –0.29, p = 0.034), percentage of final height at time 
of BA (r = –0.34, p = 0.02) and dose of fludrocortisone 
(r = –0.41, p = 0.005) on the other. There was a positive 
correlation between FAH SDS and weight (r = 0.32, 
Table 1. Clinical characteristics and hormonal profile of the study group (n = 54)
Parameters
Females (n = 40) Males (n = 14)
Median IQR Median IQR
Age (years) 23 20–28 21.5 19.25–27.25
Age of onset of puberty [yrs] 12 10–13 12 9–13
Age at menarche [yrs] 15 14–16.25 NA NA
Number of years between onset  
of puberty and menarche 3 2–4 NA NA
Dose of hydrocortisone [mg/m2/day] 15 10.35–20 16 12.42–19.5
Dose of fludrocortisone [mg/day] 0.1 0.1–0.25 0.1 0.1–0.21
17 OHP [ng/mL] 10.85 3.6–20 4.4 1.17–9.35
DHEA [ng/mL] 3.1 1.25–12.55 9.9 2.27–12.2
Delta 4 androstenedione [ng/mL] 2.35 0.95–10 0.8 0.25–1.5
Testosterone [ng/mL] 0.7 0.29–1.77 0.8 0.41–2.07
17OHP — 17-hydroxy progesterone; DHEA — dehydroepiandrosterone; IQR — interquartile range. All laboratory results reflect levels at the onset of puberty
Table 2. Auxological and bone age data in the study group 
(n = 54)
Parameters Median IQR
Target height [cm] 158.8 154.1–164.5
Target height SDS (n = 27) –0.8 –1.6 to o.15
FAH [cm] 153.50 147.15 – 159.85
FAH SDS –2.05 –2.60 to –1.30
PAH [cm] 156.80 151.65–161.90
PAH SDS –1.5 –2.4 to –0.7
Final weight SDS 0.75 –0.4 to 2.30
Final BMI SDS 1.6 0.70 to 2.50
BA at pubertal onset [yrs] 12.0 11.0–14.0
CA at time of BA [yrs] 11.50 9.0–14.0
BA–CA [yrs] 1.0 0–2.0
CA/BA [yrs] 0.94 0.82–1.0
Percentage of FAH at time of bone 
age (B&P) 90.75 88.0–94.80
FAH — final adult height; PAH — predicted adult height; BMI — body mass 
index; BA — bone age; CA — chronological age; CA/BA — chronological age/
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p = 0.02) and years between onset of puberty and 
menarche (r = 0.36, p = 0.043) (Tab. 6).
Discussion
Patients with CAH due to 21-hydroxylase deficiency 
usually show FAH values below their genetically de-
termined mid-parental target height [16].
In the current study the mean FAH attained in 
female patients with classic CAH was 150.36 ± 7.23 
cm, and in males it was 162.86 ± 3.30 cm. PAH in 
poorly controlled CAH patients using the B&P method 
showed significant overestimation of final height but 
appropriately predicted the final adult height in the 
well-controlled CAH group. A negative correlation 
was found between final adult height SD and fludro-
cortisones dose. 
Puberty relates more with skeletal than with chrono-
logical age [17], with onset in girls and boys occurring 
at approximately 11 and 13 years, respectively. For this 
reason, children with classic CAH may experience pu-
berty slightly earlier than their healthy counterparts, 
Table 4. Comparison between salt wasters and simple virilisers congenital adrenal hyperplasia (CAH) patients regarding 
chronological age/bone age (CA/BA) at time of puberty, final adult height (FAH), and final adult height/target height (FAH/TH) 
Mean ± SD 
(range)
Type of CAH
p valueSalt wasters 
(n = 23)
Simple virilisers  
(n = 31)


















SD — standard deviation
Table 5. Differences between predicted vs. final adult height standard deviations (SDs) in patients with good control and 




Median (IQR) p value
Good control (n = 8) –1.7 (–2.5, –1.4) –1.5 (–2.7, –1.35) 0.37
Poor control (n = 46) –1.4 (–2.3, –0.75) –2.1 (–2.6, –1.2)  < 0.001
PAH — predicted adult height; FAH — final adult height
Table 3. Differences between males vs. females (SW vs. SV) (those on hydrocortisone dose < 15 mg/m2/d vs. those on > 15 mg/
m2/d) in each sex group (n = 54) with regard to mean final (FAH) and predicted (PAH) adult height and their SDS 
Parameters Males (n = 14) Females (n = 40) p value
FAH [cm] 162.86 ± 3.30 150.36 ± 7.23  < 0.001
FAH SD –1.53 ± 0.51 –2.05 ± 1.13 0.048
PAH SD –0.5 ± 0.50 –1.57 ± 1.3 0.39
FAH-PAH SD –0.72 ± 0.41 –0.50 ± 0.96 0.62
SW (n = 5) SV (n = 9) SW (n = 18) SV (n = 22)
FAH SD –2.5 ± 0.44 –1.33 ± 0.38 –2.12 ± 1.14 –1.97 ± 1.15
p value 0.01 0.67
HC < 15 mg/m2/d 
(n = 7)
HC > 15 mg/m2/d 
(n = 7)
HC < 15 mg/m2/d 
(n = 20)
HC > 15 mg/m2/d 
(n = 20)
–1.31 ± 0.25 –1.84 ± 0.59 –2.02 ± 1.19 –2.04 ± 1.13
p value 0.04 0.93
HC — hydrocortisone; SD — standard deviation; SW — salt-wasting; SV — simple-virilising
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with the SV form being associated with the earliest 
puberty [18]. 
The median age at onset of puberty in our study was 
12 years, with a wide range from 7 to 16 years reflect-
ing the early puberty of SV children and the markedly 
delayed puberty of the uncontrolled females with hy-
perandrogenaemia and/or PCOS. Menarche occurred 
at a median age of 15 years. In the Klingensmith et al. 
study [19] 92% of patients with menstrual delay had 
inadequate suppression of adrenal androgens due to 
poor compliance or insufficient doses of glucocorticoids 
(puberty is associated with increased cortisol clearance) 
[20], as occurred with the girls in our study. Onset of 
menarche was very much delayed and subsequently 
irregular in three of the female patients in our study 
group. In two (with 6- and 7-year delays), the reason was 
PCOS, which occurs in 30-40% of women with CAH [21]. 
In our study, however, there was no correlation 
between the age at onset of puberty (or age at men-
arche) with FAH, and there was a negative correlation 
between the number of years between onset of puberty 
and menarche and FAH SD (p = 0.043). This may be 
related to higher androgen levels in poorly controlled 
females, accelerating skeletal maturity while also delay-
ing menarche.
 The difference between bone age and chronological 
age in our patients showed a mean one-year advance-
ment. Also, our patients had reached 70–99.8% of their 
final height (mean ± SD: 90.56 ± 6.9%). Healthy girls on 
average have a total gain in height of 25 cm during the 
pubertal period compared to 28 cm in boys [9]. Height 
attainment in our patients through puberty was low, the 
assumption being that there was early skeletal matu-
ration and closure of the epiphyses and/or decreased 
pubertal growth spurt [22, 23]. Researchers studying the 
relationship between bone maturation and degree of 
17OHP control found that BA was significantly delayed 
with tight control and significantly advanced by poor 
control [24]. Evidence derived from a meta-analysis 
of observational studies suggests that FAH in CAH is 
lower than both the population norm and target height 
[25]. This was not significantly associated with age at 
diagnosis, gender, type and dose of steroid, or age of 
onset of puberty.
Serum 17OHP is the traditional indicator of ad-
equacy of glucocorticoid treatment in CAH. Complete 
suppression of 17OHP levels is not a treatment goal 
but rather indicates overtreatment [7]. In our study, 
17OHP levels ranged from extremely suppressed to 
very high values, indicating poor control at either of 
the two extremes. A disappointingly low percentage 
of our patients (14.8%) had desired levels of 17OHP. In 
this group, B&P was able to accurately predict FAH at 
the onset of puberty. This was not the case in children 
with poor control, in whom B&P tended to overesti-
mate FAH by 0.7 SDS. Bone age at the onset of puberty 
had a negative correlation with FAH SD. Although 
FAH was significantly lower than target height in all 
patients and FAH was not significantly better in those 
with good control, it should be noted that a median of 
–1.5 SD suggests that optimal control at puberty may 
result in height within the normal range [26]. B&P is 
usually intended for use in healthy children, but stud-
ies have employed this method to evaluate the effect of 
growth-promoting therapies in patients with CAH [27].
The B&P method assists with height prediction by 
estimating the percentage of height already achieved, 
but it tends to overestimate FAH when compared to 
projected height in patients with advanced BA, and 
underestimate it with delayed BA [28]. 
The weights and BMIs in our study cases tended to 
be high. Our findings agree with those of Al Shaikh et 
al. [29], who concluded that children and adults with 
CAH are at an increased risk of developing obesity. 
Sarafoglou et al. showed that higher glucocorticoid 
dosage and advances in CA and BA were associated 
with an elevated BMI and obesity [30]. FAH correlated 
with body weight but not with BMI in our patients. This 
agrees with other studies in which obesity in CAH pa-
tients appeared to be correlated with reduced height 
potential [31].
Height outcome is related to the dose of corti-
costeroid, with some authors describing a negative 
correlation between hydrocortisone doses and FAH 
[32]. Although we noted that FAH in males on steroid 
doses ≤ 15 mg/m2/day was significantly higher than in 
those receiving higher doses, we found no correlation 
between the actual dose of steroids and FAH, suggest-
ing that growth is maintained within this cut-off dose.
Table 6. Correlations between final adult height (FAH), 
standard deviation (SD), and different clinical and biochemical 
parameters
Correlations R p value
FAH SD and BA at onset of puberty –0.29 0.034
FAH SD and percentage of FAH  
at time of BA –0.34 0.02
FAH SD and hydrocortisone dose  
[mg/m2/day] –0.11 0.43
FAH SD and dose of fludrocortisones  –0.41 0.005
FAH SD and weight 0.32 0.02
FAH SDS and BMI –0.04 0.77
FAH SD and years between onset  
of puberty and menarche in girls 0.36 0.043
Dose of hydrocortisone and 17-OH 
progesterone 0.304 0.027
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In addition to its mineralocorticoid action, its corti-
sone-like effect has resulted in the use of fludrocortisone 
as a steroid-sparing drug [5]. This has proven efficacious 
in many cases. Although only 23 of our patients had 
SW CAH, a total of 46 were receiving fludrocortisones 
as per the latest Endocrine Society clinical practice 
guidelines. These guidelines indicated that aldoste-
rone deficiency is present in all forms of classic CAH 
although it is clinically apparent only in SW form [7]. 
Having said that, we noted that within the group of 
fludrocortisone-users (82%) the actual dose correlated 
negatively with FAH (p = 0.005). A recent study by 
Sellick et al. highlighted the importance of recogniz-
ing the glucocorticoid activity of fludrocortisone when 
calculating replacement regimens [33]. 
Although growth tends to be more severely affected 
in SW children < 2 years of age because of salt loss and 
the need for higher doses of glucocorticoid [34], we 
found no difference in FAH between the SV and SW 
groups. This concurs with the findings of Manoli et al. 
[35]. However, males with SV CAH had significantly 
higher FAH SD than males with SW (p = 0.01). This 
difference was not observed in females. This finding 
contradicts that of Nguyen et al., who recorded the 
poorest height prognosis in males with SV [31], and 
Pijenburg-Kleizen et al., who also described the worst 
FAH in children with SV CAH. They related this in 
part to late diagnosis and treatment and BA advance-
ment. This male/female difference in height outcome in 
CAH patients where males fare more poorly has been 
described in other studies [34]. 
Treatment during puberty has to be individualised 
not only for growth but also because inadequate control 
has implications for future reproductive and sexual 
health. On the other hand, Cushing syndrome should 
be avoided [4]. 
Limitations
Because CAH is such a heterogenous disease in itself 
and because many adolescents are lost to follow-up, 
it was not possible to provide a more homogenous 
group of patients who fulfilled the inclusion criteria. 
Also, due to incomplete files, we were unable to calcu-
late cumulative hydrocortisone doses received in the 
prepubertal years.
Conclusions and recommendations
B&P prediction can predict FAH in children with CAH 
at the onset of puberty if they are well-controlled, 
but it will overestimate FAH if not well controlled. 
The heights of females with CAH, males with SW, or 
all those on high doses of hydrocortisone are lower 
than their genetic potentials. CAH is a heterogenous 
disease and the division of patients into SW and SV 
is arbitrary and simplistic. The true situation is that 
the disease is a continuum with many cases fitting 
somewhere between the two extremes. Management 
of the many problems of patients with CAH presents 
a unique challenge.
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